Although LRYGB resulted in greater weight loss, it was associated with a 4.6% higher total morbidity rate
Clinical Evidence for Weight Loss and Metabolic Health A Phase 2 trial published in NEJM (2023) reported approximately 24.2% mean body weight reduction over 48 weeks at the highest dose, alongside improvements in fasting glucose, insulin sensitivity, triglycerides, and waist circumference
By forty, it's dropped by roughly 40%
In STZ-induced DN mouse kidney sections, the outer mitochondrial membrane ruptured, mitochondrial crista disappeared, ACSL4 expression was significantly increased, the levels of oxidative products were elevated, and the level of GPX4 was decreased, indicating that ferroptosis was involved in STZ-induced DN [225]